Lymphoma Clinical Trials | Norton Healthcare Louisville, Ky.

Lymphoma Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Active lymphoma trials at Norton Cancer Institute include:

Hematological Malignancies

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Hematological Malignancies

Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

Hematological Malignancies

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Hematological Malignancies

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Hematological Malignancies

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who A

Hematological Malignancies

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Hematological Malignancies

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Hematological Malignancies

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLB

Hematological Malignancies

Phase 1b/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Miscellaneous Malignancies

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

UVB light as a treatment for cutaneous lymphoma

Ultraviolet light, specifically, narrowband UVB light, can reduce skin inflammation, especially as a treatment for eczema and psoriasis. A Louisville-area dermatologist is using this therapy as a treatment for cutaneous T-cell lymphoma, a blood cell […]

Read Full Story

In sickness and in health

The lump on Lonnie Gardner’s left arm looked innocuous. Maybe an insect bite, he reasoned. For weeks in 2014, the human resources professional went about his business, unconcerned. But the lump got larger and caught [...]

Read Full Story

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped [...]

Read Full Story

Norton cancer specialist’s research paves way for new FDA-approved lymphoma treatment

The U.S. Food and Drug Administration recently approved a new cancer drug that has been available only to patients enrolled by a Norton Cancer Institute physician and one other researcher nationwide. Don A. Stevens, M.D., [...]

Read Full Story
Related Stories

UVB light as a treatment for cutaneous lymphoma

Ultraviolet light, specifically, narrowband UVB light, can reduce skin inflammation, especially as a treatment for eczema and psoriasis. A Louisville-area dermatologist is using this therapy as a treatment for cutaneous T-cell lymphoma, a blood cell […]

Read Full Story

In sickness and in health

The lump on Lonnie Gardner’s left arm looked innocuous. Maybe an insect bite, he reasoned. For weeks in 2014, the human resources professional went about his business, unconcerned. But the lump got larger and caught [...]

Read Full Story

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped [...]

Read Full Story

Norton cancer specialist’s research paves way for new FDA-approved lymphoma treatment

The U.S. Food and Drug Administration recently approved a new cancer drug that has been available only to patients enrolled by a Norton Cancer Institute physician and one other researcher nationwide. Don A. Stevens, M.D., [...]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.